SCHEMBL18009759

SCHEMBL18009759

Cc1nc(C)c2ccn([C@@H]3O[C@H](CO[Si](C)(C)C(C)(C)C)[C@H]4OC(C)(C)O[C@H]43)c2n1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.35
DUT P33316 1/20 0.34
PI4KA P42356 1/20 0.33
PI4K2B Q8TCG2 1/20 0.33
PI4K2A Q9BTU6 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
P2RX1 P51575 1/20 0.33
P2RX3 P56373 1/20 0.33
P2RX4 Q99571 1/20 0.33
PRMT5 O14744 8/20 0.32
WDR77 Q9BQA1 8/20 0.32
ALDH1A1 P00352 2/20 0.31
LMNA P02545 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
APOBEC3G Q9HC16 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18056025 1.00 RXFP1 (0.35) RXFP1DUTPI4KAPI4K2BPI4K2A
SCHEMBL18572819 0.92 PRMT5 (0.34) RXFP1DUTPI4KAPI4K2BPI4K2A
SCHEMBL18009882 0.87 PRMT5 (0.42) RXFP1PI4KAPI4K2BPI4K2API4KB
SCHEMBL18009860 0.86 RXFP1 (0.34) RXFP1DUTPI4KAPI4K2BPI4K2A
SCHEMBL18572203 0.85 RXFP1 (0.34) RXFP1DUTPI4KAPI4K2BPI4K2A
SCHEMBL31526303 0.84 RXFP1 (0.39) RXFP1PI4KAPI4K2BPI4K2API4KB
SCHEMBL18026299 0.83 PI4KA (0.38) RXFP1PI4KAPI4K2BPI4K2API4KB
SCHEMBL25354004 0.83 RXFP1 (0.39) RXFP1DUTPI4KAPI4K2BPI4K2A
SCHEMBL12374615 0.83 RXFP1 (0.39) RXFP1DUTPI4KAPI4K2BPI4K2A
SCHEMBL22334000 0.83 RXFP1 (0.39) RXFP1DUTPI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262057-B1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2020-04-15 EP disclosed
US-10428104-B2 Substituted nucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-10-01 US disclosed
US-10428104-B2 Substituted nucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-10-01 US disclosed
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428104-B2 Substituted nucleoside derivatives useful as anticancer agents TYMP, NME1, DPYD RXFP1 4876/4885DUT 5/4885PI4KA 769/4885
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS TYMP, NME1, PNP RXFP1 4862/4885DUT 5/4885PI4KA 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.